VIR Vir Biotechnology

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

SAN FRANCISCO--(BUSINESS WIRE)--

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March:

  • TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston. Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Monday, March 4, at 2:50 p.m. ET / 11:50 a.m. PT.
  • Leerink Partners Global Biopharma Conference at the Fontainebleau Hotel in Miami Beach. Vir management will be hosting one-on-one investor meetings on Monday, March 11 and Tuesday, March 12.
  • Barclays 26th Annual Global Healthcare Conference at Loews Miami Beach Hotel in Miami. Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Tuesday, March 12, at 7:30 a.m. ET / 4:30 a.m. PT.

Live webcasts of the fireside chats can be accessed under Events & Presentations in the Investors section of the Vir website at and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

EN
23/02/2024

Underlying

VIRVir Biotechnology

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vir Biotechnology

 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology Provides Corporate Update and Reports First Quarter ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the significant unmet medical need for the millions of people living with hepatitis delta,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer. “Our team has worked diligently to streamline our operations and reduce costs,...

May 2, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology to Participate in the BofA Securities Healthcare Con...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is an immunology company focused on powering the immune syst...

April 30, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D....

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”). If elected, each of Drs. Bischofberger and Farid will join the Board on such date. The nomination of the two new independent directors demonstrates Vir’s commitment to ongoing Board refreshment. Drs. Bischofberger and Farid bring extensive mid-to-late-stage clinical development and computat...

April 18, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology to Provide Business Update and Report First Quarter ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at . Participants may access the conference call via webcast on the Events & Present...

April 11, 2024 1 EN
 PRESS RELEASE
Free
VIR Vir Biotechnolo...

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis De...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating the combination of tobevibart and elebsiran given every 4 weeks. Initial data are expected in the sec...

March 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch